KalVista Pharmaceuticals (“KalVista”) and JDRF have formed a research partnership focused on a novel approach being developed by KalVista to preserve vision and slow the progression of diabetic eye disease. Diabetic eye disease is one of the most common and most serious complications in people with type 1 diabetes (T1D). JDRF will...

A new study has found that long-term risk of an impaired glomerular filtration rate (GFR), which leads to end-stage renal disease and increases the risks of cardiovascular disease and death, was significantly lower among persons treated early in the course of type 1 diabetes with intensive diabetes therapy than among those treated...

A new study has found vitamin D deficiency to be associated with retinopathy in children and adolescents with type 1 diabetes. The study, published online ahead of print in Diabetes Care, set out to examine the hypothesis that vitamin D deficiency is associated with...

Pluristem Therapeutics, Inc., an Israeli based company developing placenta-based cell therapies, and New York University (NYU) Medical Center today announced the formation of a partnership to study the use of Pluristem’s proprietary placenta-derived PLX cells for the treatment of diabetic foot ulcers. Weiliam Chen, R.Ph. Ph.D., Director...

Abbott has announced positive results from a Phase 2, 8-week dose-ranging study using low doses of atrasentan in patients with diabetic kidney disease. The results suggest that atrasentan, used in conjunction with renin-angiotensin system (RAS) inhibitors, may reduce albuminuria (presence of protein in urine) for patients with type...

A statin drug (Lipitor) may help prevent blindness in people with diabetes, according to researchers at the University of Georgia College of Pharmacy.  In a study using diabetic rats and isolated retinal cells cultured in high glucose, lead author Azza El-Remessy, assistant professor in the University of Georgia College of Pharmacy,...

Harvard University and  Hebrew University scientists have developed a low cost, nanometer-sized drug to treat chronic wounds, such as diabetic foot ulcers or burns. Several proteins, called growth factors, have been found to speed up the healing process, however purifying these growth factor proteins is very expensive, and they...

The European Commission has granted Novartis a new indication for Lucentis (ranibizumab) to treat patients with visual impairment due to diabetic macular edema (DME) following two Novartis-sponsored clinical trials, RESTORE and RESOLVE.  The trials showed that Lucentis was superior in providing rapid and sustained visual acuity gain...

Data from a Phase 2b study suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in the majority of patients receiving the drug. Reata Pharmaceuticals and Abbott presented...

Novartis has announced that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Lucentis (ranibizumab) for the treatment of patients with visual impairment due to diabetic macular edema (DME). The submission was supported by data from two Novartis-funded clinical trials, RESTORE and...